Back to All

ASCO Daily Highlights Day 2 Saturday 3rd June

4 June, 2023

Our team of precision medicine experts are today at ASCO in Chicago gaining insight into all of the new advancements in oncology impacting patients. Read on to discover the team's top three announcements and highlights from a vibrant day 2 at the conference yesterday.

1. Agendia Precision Oncology Announcement.  In addition to its existing prognostic and predictive diagnostic test MammaPrintTM which is used to assess the metastatic risk of early stage breast cancer, Agendia have announced their new breakthrough biomarker signature platform-ImPrint has now received FDA IDE status and is being used to identify/stratify patients who will benefit from the addition of immunotherapy for trials (eg. neoadjuvant I-SPY2 trial for early-stage breast cancer).*  We believe this could have a great impact on patients as a good uptake of the ImPrint testing can enhance the efficacy and safety of I/O in treating early-stage breast cancer patients.

*Source: abstract #102 talk “Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS)” & accompanied commentary talk “I-SPY Biomarkers of Immunotherapy Response: Neoadjuvant Immunotherapy Trials as a Platform for Biomarker Discovery”

2. Minimal Residual Disease (MRD) testing continues to be a key topic this year.

MRD testing is a rapidly growing topic in the field of cancer and has received many recognitions during the 2023 ASCO annual meeting with 443 MRD related abstracts and presentations.*  At Diaceutics we predicted that the clinical utility of MRD in cancer care can be expanded from previously well-established disease surveillance to possibly acting as;

1. Predictive testing for the treatment outcome in Sarcoma.

2. Clinical trial endpoint (co-primary endpoint or c-secondary endpoint) for the treatment of newly diagnosed and relapse/refractory multiple myeloma.

*Source: abstract #8000 talk “Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study”; abstract#11509 talk “Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS)”; abstract#11510 talk “The clinical value of tumor-informed minimal residual disease detection in sarcoma”; abstract #11511 talk “Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial”; abstract #11512 talk “Deep learning with whole slides images to predict histological response to neoadjuvant chemotherapy in patients with resectable high grade soft-tissue sarcomas: A multicenter study”; abstract #8006 talk “LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma”.

3. New opportunities for MCED testing to improve patient outcomes through early detection. 

 The positive results from the NHS clinical trial, SYMPLIFY study and the PATHFINDER study, promise the use of a multi-cancer early detection, (MCED), test to achieve optimal treatment outcomes in cancer care via early detection.  Clinical trials involving greater numbers of patients are currently ongoing to clarify the tests’ predictive ability towards different cancer types and the screening strategies of MCED.*

Our team anticipate that the early findings of the predictive values of the MCED test in both the clinical trial and the real-world setting suggest opportunities for the adoption of the MCED test in cancer clinical routine care.

*Source: abstract #10519 talk “Early real-world (RW) experience with a multi-cancer early detection (MCED) test”; abstract #1501 talk “Large-scale observational prospective cohort study of a multi-cancer early detection (MCED) test in symptomatic patients referred for cancer investigation”; abstract #10520 talk “Clinical evaluation of cancer signal origin prediction and diagnostic resolution following multi-cancer early detection testing” and abstract # 10521” Real-world performance of a multi-cancer early detection test based on integrative analysis of cell-free DNA whole-methylome sequencing”.

Contact us to discuss how our in-house precision medicine experts can support your commercialization strategy goals:

What to know more about MRD testing?  Discover our latest report here:

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny